Acknowledging the FDA conducted a thorough investigation and made a hard decision to propose withdrawing marketing approval for Avastin for metastatic breast cancer, we still want another public hearing to be held. We sent a letter yesterday to the FDA encouraging the agency to hold a hearing to talk about the appeal made by Avastin’s maker, Genentech/Roche.
The FDA cited studies indicating Avastin did not affect overall survival of metastatic breast cancer patients and had significant side effects for many.
However, we also know that for some number of women, Avastin works and works well. We have heard from women who are gaining not just months, but years, with a high quality of life, from this treatment. We are concerned about the potential impact on women who are currently benefiting from Avastin if the FDA removes its approval for its use as a treatment for metastatic breast cancer. We want to be sure that women who are using Avastin, and for whom it is working, can continue to have access to it, and that their insurers will continue to pay for it.
We also want Genentech/Roche to keep making the drug available to women through its patient support programs, consider an expanded access program and continue research on a biomarker for Avastin to determine which women will benefit from the drug.The full text of the letter is available here
Did you know that breast cancer isn’t just one disease, but rather a disease made up of several subtypes, one of which is triple negative breast cancer?
Triple negative breast cancers are estrogen receptor-negative (ER-), progesterone receptor-negative (PR-) and HER2/neu-negative (HER2-) and about 15 to 20 percent of breast cancers are categorized as such. It’s important to note these tumors tend to occur more often in younger women and African American women. And, many BRCA1 and BRCA2 breast cancers also happen to be triple negative.
These triple negative tumors are often aggressive and have a poorer prognosis compared to the estrogen receptor-positive cancers. Treatment plans usually include some combination of surgery, radiation therapy and chemotherapy.
Although the reasons why younger African American women get triple negative breast cancer are not clear right now, one study suggests lifestyle factors might play a role. And higher rates of triple negative tumors may explain, to some degree, the poor prognosis of breast cancers diagnosed in younger African American women.
To learn more about triple negative breast cancer in African American women, we invite you to register for our upcoming webinar on Monday, Feb. 14 – Triple Negative Breast Cancer in the African American Woman – from 3-4 p.m. CST / 4-5 p.m. EST. Our two speakers for the hour will be Dr. Olufunmilayo Olopade from the University of Chicago Medical Center and survivor and Komen advocate, Tina Lewis. Check out the Facebook event here.Register for the webinar now!
Learn more about Triple Negative Breast Cancer here.
A long-standing surgical routine affecting tens of thousands of women every year may be changing because of a new study and others like it. The newest study, published this week in the Journal of the American Medical Association, has the potential to provide new options for women facing treatment for early stage breast cancers. It found that routine removal of the lymph nodes in someone’s armpit (known as an axillary lymph node dissection, or ALND) doesn’t improve survival or recurrence rates, and is not necessary for some women.
This means that a significant percentage of newly diagnosed breast cancer patients could avoid this painful surgery, which carries serious side effects — the most common of which is lymphedema, an incurable swelling in the arm that can range from mild to disabling. Women in the study who had their nodes removed also were much more susceptible (70% vs. 25%) to complications such as infections, strange sensations and abnormal fluid buildup in the armpit, the study found.
This study and similar recent research are a continuation of a trend toward less invasive surgery for women with breast cancer, and will provide new treatment options for many women. We encourage women to have a frank discussion with their surgeons about whether this approach is suitable for them. We expect that this option will be available first at major breast centers and with surgeons who specialize in breast cancer surgery.
In a TIME article, our president, Liz Thompson joins the study’s authors in discussing the implications on those affected by breast cancer.
“Patients may or may not be ready because we have been taught that with surgery, radiation and chemotherapy, more is better.”
-Liz Thompson, president of Susan G. Komen for the Cure®
We have invested $2.5 million researching the causes and potential treatments for lymphedema and has also funded studies into the use of sentinel lymph nodes as an alternative to axillary node dissection.
Learn more about lymph node status, SNB and ALND here.
Twenty years ago, we celebrated a tremendous victory in our effort to ensure access to vital breast health services for women in need. Today, as that victory is facing its toughest challenge to date, our leadership is needed again.
With the launch of the National Breast and Cervical Cancer Early Detection Program, women who were falling through the cracks of our health care system and needed help were finally receiving it. It was a momentous, and truly life-saving, achievement.
Since that day, the entire Susan G. Komen for the Cure family has worked tirelessly to educate women in need about this program and to push policymakers to increase their investments so we could reach all women in need. At the same time, we’ve looked for ways to expand access through our community grants and collaboration with providers. The screening program also gave us the opportunity to invest in other important programs to improve the effectiveness and efficiency of the breast health system.
Now, with economic conditions that are straining every state budget, everything we have fought for and everything we have accomplished is at risk.
How big is the problem? Three out of every four states are facing budget holes that range between 5 percent of their total budget, to more than half! That means every program, no matter its worth, is at risk of being cut or eliminated – this includes breast cancer screening and treatment programs. Once believed impossible, this threat is real.
Our experience in California last year, where the screening program was shut down for several months, teaches us that breast cancer screening is not untouchable. Yet as the program was restored last fall, and was preserved in the Governor’s new budget proposal, the California example also teaches us that our voice can be formidable.
We must be vigilant, and not assume any state is safe. Just consider Washington State where Governor Gregoire, herself a breast cancer survivor, proposed a 25% cut in the program, which would zero out state funding for the remainder of the Fiscal Year and reduce access to 5,000 women.
We understand the difficult choices that elected officials are facing. Yet, we also see firsthand the importance of this program – it is there to ensure a lost job and lost insurance doesn’t mean a lost life. These women are our mothers and our sisters; our friends and our neighbors. And they don’t disappear just because the state stops screening them, and neither does their cancer – it just grows undetected.
In Washington State, we’ve already begun to make our voices heard and the initial results are encouraging. Yet Washington is just the first of many states where the Komen family may have to answer the call.
We need your help. We need you to raise your voice and let your elected leaders know how important this program is and that it is imperative that the program’s funding be preserved.
Please contact your local Affiliate to see how you can help. Find your local Affiliate here.
During Black History Month, we’re honoring the African American researchers and clinicians who are helping to create a world without breast cancer. We start with one of the most highly regarded cancer surgeons in the country, our former board chairman known for his skill and compassion.
“When you grant patients hope, you grant them one of the greatest of all human joys, and that is the joy of anticipation, that perhaps, just maybe, there is something that can be done to help them.”
-Dr. LeSalle D. Leffall, Jr.
From the age of nine, LaSalle D. Leffall, Jr., knew he wanted to be a doctor. The inspiration? A wounded bird he nursed back to health.
In September 1945, at the age of 15, he enrolled in the pre-med program at Florida A&M, Florida’s only state-supported, historically black college. Three short years later, Leffall entered Howard University’s College of Medicine in Washington, D.C., and graduated in 1952 at the top of his class. Dr. Leffall’s medical training continued with an internship in St. Louis, residency in Washington, D.C., and a surgical fellowship at Memorial Sloan-Kettering Cancer Center in New York City. He returned to Howard University in 1962 as a faculty member and went on to serve as Acting Dean of the Medical School and Chairman of the Department of Surgery.
Surgery was his calling; he was drawn to the precision, decisiveness, and efficiency of the specialty. Dr. Leffall’s mentors influenced his decision to further specialize in surgical oncology and pursue the fellowship at Memorial Sloan-Kettering. A turning point in his career, it led him back to Howard where he was able to pursue his talents as a cancer surgeon and teacher. Leffall has devoted much of his professional life to the study of cancer, particularly as it affects African Americans. He and his colleagues at Howard authored some of the early papers on disparities in cancer outcomes, including an important article in 1973 that brought to light the alarming increase in cancer mortality in black Americans.
Through various leadership positions, Dr. Leffall has helped shape the U.S. cancer agenda and create programs to address healthcare disparities. He was the first African American president of the American Cancer Society, the Society of Surgical Oncologists, and the American College of Surgeons, and a founding member of the National Dialogue on Cancer (now C-Change). In 2002, President George W. Bush appointed Dr. Leffall to chair the President’s Cancer Panel, a 3-member group that monitors national cancer programs and reports on progress and obstacles to cancer control.
In 2010, we honored Dr. Leffall, who is also our former board chair, for his pioneering work and leadership in cancer health disparities.
One of Dr. Leffall’s enduring contributions has been to train future generations of doctors. During his career at Howard University, he taught an estimated 5,000 medical students and helped train nearly 300 surgical residents. He quotes Henry Adams as he reflects on his love of teaching, “A teacher affects an eternity.” No doubt, Dr. Leffall’s influence as a mentor and clinician will extend for generations to come.